Foresight Diagnostics

#ForesightDx is looking forward to attending the Advancing Precision Medicine Conference in Philadelphia, PA, on November 1 and 2. Our research partner Dr. Mark Roschewski will discuss how advancements in ultra-sensitive #ctDNA technology may help evolve the precision medicine landscape in #lymphoma. Please join us for his presentation on November 1st at 4:45pm ET. Our Chief Business Officer John Truesdell and our Chief Operating and Compliance Officer Sandra Close will be attending. Interested in meeting? Schedule time to meet with our team here: Online: https://t.ly/FWBrA Email: BD@foresight-dx.com #PrecisionMedicine #AdvancingPrecisionMedicine #LiquidBiopsy #MRD #ForesightCLARITY #CancerResearch

#ForesightDx had an amazing time participating in The Susan G. Komen More Than Pink Walk this past weekend. Thank you to everyone who donated to our team. It was great to #connect to our #mission and see first hand the #impact our work could have on people affected by #cancer. See our most recent data in breast cancer here: https://t.ly/A2aQY #BreastCancerAwareness #MorethanPink #PinkWalk #PrecisionMedicine #LiquidBiopsy #MRD #ForesightCLARITY

Our partner Allogene Therapeutics will be speaking at the STAT Summit Conference on October 16th and 17th to discuss innovation in CAR T.     For more information and to register: https://t.ly/lKza2 #MRD #ctDNA #PrecisionMedicine #LiquidBiopsy #CancerResearch #ForesightDx #CART

#ForesightDx is proud to support organizations dedicated to improving the lives of cancer patients worldwide. In line with this mission, we invite you to help us raise money at our next volunteer event: The Susan G. Komen Foundation More than Pink Walk on Saturday October 12, 2024.    Please see our donation page here: https://t.ly/UezTP If you're able, we encourage you to donate to our team—every contribution makes a difference! #MorethanPink #BreastCancerAwareness #PinkWalk #MRD #CancerResearch #Fundraising

#ForesightDx proudly supports Breast Cancer Awareness Month, raising awareness and standing with those affected. Breast cancer mortality has decreased due to improved screening and treatment options. Nevertheless, 25-30% of patients develop disease #recurrence. Minimal residual disease (#MRD) detection has the opportunity to identify risk of #relapse sooner to improve our ability to #treat patients effectively. Let us continue to raise awareness on the importance of bringing #surveillance and early #detection technologies to clinicians and patients. Check out our recent poster showcasing new data on Foresight CLARITY™ ultra-sensitive MRD platform in early-stage breast cancer: https://t.ly/GIv9u #BreastCancerAwareness #BreastCancer #October #ThinkPink #ThinkBeforeYouPink #ForesightCLARITY #PrecisionMedicine #ctDNA

#ForesightDx had an amazing time participating in The Leukemia & Lymphoma Society's Light The Night walk in Denver, CO. A huge thank you to everyone who donated to support treatments for patients battling all forms of blood cancer. We look forward to joining this incredible cause again next year. #LightTheNight #LLS #ForesightCLARITY #BloodCancerAwarenessMonth #PrecisionMedicine #LiquidBiopsy

#ForesightDx proudly recognizes World Cancer Research Day, raising awareness of the vital role #cancer research plays in driving advancements in #prevention, #treatment, and #survival rates—helping to reduce the global cancer burden.  See our latest research in cancer relapse detection using our ultra-sensitive liquid biopsy platform, Foresight CLARITY ™: https://t.ly/V7Sid #WorldCancerResearchDay #CancerResearch #LiquidBiopsy #PrecisionMedicine #ForesightCLARITY #MRD #ctDNA 

#ForesightDx will be participating in The Leukemia & Lymphoma Society (#LLS) Light The Night walk in Denver, CO on Thursday, September 26, to help raise funds and awareness in the fight against blood cancer.    Donations raised through Light The Night allow LLS to fund #treatments for patients who are suffering from all forms of blood cancers. LLS has helped fund over 70% of FDA-approved blood #cancer treatments since 2016.    We welcome donations to our team page: https://t.ly/WC_1J    #LightTheNight #LLS #ForesightCLARITY #BloodCancer #PrecisionMedicine #LiquidBiopsy

#ForesightDx had a great ESMO Congress 2024.     We presented our poster featuring Foresight CLARITY™ in early-stage breast cancer. This exploratory study demonstrates the opportunity to use ultra-sensitive #MRD for adjuvant and neo-adjuvant #therapy determination following curative-intent surgery.    See our poster here: https://t.ly/-keRV   We’re grateful for a #successful #ESMO24 and for the patients who are waiting for us to deliver.     Thank you to our #collaborators and #partners. We look forward to seeing everyone next year! #BreastCancer #ctDNA #PrecisionMedicine #SolidTumor #collaboration  #ForesightCLARITY #PhasedSeq

If you’re in Barcelona for #ESMO24, stop by our poster today showcasing new data on Foresight CLARITY™ ultra-sensitive MRD platform in early-stage breast cancer in collaboration with our partners at Memorial Sloan Kettering Cancer Center (MSK) and Stanford University. Lead author Luc Cabel will be in attendance at the poster from 12-1pm CEST for questions and discussion. #ESMO24 #MRD #MSK #ForesightCLARITY #Relapse #Recurrence #solidtumor #BreastCancer #PrecisionMedicine